Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,622,946
  • Shares Outstanding, K 141,742
  • Annual Sales, $ 45,610 K
  • Annual Income, $ -180,970 K
  • 60-Month Beta 1.09
  • Price/Sales 34.16
  • Price/Cash Flow N/A
  • Price/Book 3.48
Trade AUPH with:

Options Overview Details

View History
  • Implied Volatility 96.69% ( +3.07%)
  • Historical Volatility 109.27%
  • IV Percentile 19%
  • IV Rank 25.64%
  • IV High 167.23% on 12/03/21
  • IV Low 72.38% on 07/22/21
  • Put/Call Vol Ratio 0.20
  • Today's Volume 2,489
  • Volume Avg (30-Day) 3,024
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 161,069
  • Open Int (30-Day) 142,013

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.19
  • Low Estimate -0.25
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +40.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.86 +26.52%
on 05/09/22
11.87 -5.56%
on 04/21/22
-0.09 (-0.80%)
since 04/18/22
3-Month
8.86 +26.52%
on 05/09/22
17.31 -35.24%
on 02/22/22
-6.23 (-35.72%)
since 02/18/22
52-Week
8.86 +26.52%
on 05/09/22
33.97 -67.00%
on 11/03/21
-1.84 (-14.10%)
since 05/18/21

Most Recent Stories

More News
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that...

AUPH : 11.21 (-2.10%)
INVESTOR DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7, 2021 and February 25, 2022, both dates...

AUPH : 11.21 (-2.10%)
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 11.21 (-2.10%)
OPTN : 1.99 (-1.97%)
Aurinia Reports First Quarter 2022 Financial and Operational Results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2022. Amounts, unless specified otherwise, are expressed in...

AUPH : 11.21 (-2.10%)
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement...

AUPH : 11.21 (-2.10%)
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022,...

AUPH : 11.21 (-2.10%)
3 Healthcare Companies With Revenue Spiking 100% or More

Here's why three Fool.com contributors are bullish on Outset Medical, Aurinia Pharmaceuticals, and Shockwave Medical.

OM : 23.88 (-8.51%)
AUPH : 11.21 (-2.10%)
SWAV : 162.34 (-1.89%)
AUPH Stock News: Robbins LLP Investigates Aurinia Pharmaceuticals Inc. (AUPH) on Behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) and its officers and directors to determine whether they breached their fiduciary duties and violated...

AUPH : 11.21 (-2.10%)
DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7, 2021 and February 25, 2022, inclusive...

AUPH : 11.21 (-2.10%)
Bronstein, Gewirtz & Grossman, LLC Notifies Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Encourages Investors to Contact the Firm

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ:...

AUPH : 11.21 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

3rd Resistance Point 11.90
2nd Resistance Point 11.69
1st Resistance Point 11.45
Last Price 11.21
1st Support Level 11.00
2nd Support Level 10.79
3rd Support Level 10.55

See More

52-Week High 33.97
Fibonacci 61.8% 24.38
Fibonacci 50% 21.42
Fibonacci 38.2% 18.45
Last Price 11.21
52-Week Low 8.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar